Estradiol
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar Atrophy
Conditions
Vulvar Atrophy, Vaginal Atrophy
Trial Timeline
Nov 6, 2012 → Apr 30, 2013
NCT ID
NCT01753102About Estradiol
Estradiol is a phase 3 stage product being developed by Sun Pharmaceutical for Vulvar Atrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01753102. Target conditions include Vulvar Atrophy, Vaginal Atrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01753102 | Phase 3 | Terminated |
Competing Products
7 competing products in Vulvar Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 52 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 51 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 51 |
| AVA6103 | Avacta Group | Phase 1 | 25 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 44 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85